Key Takeaway: Aytu BioScience, Inc. Proforma Balance Sheet June 30, 2017 Unaudited
6/30/2017 Pro Forma Pro Forma Consolidated Adjustments (a) Combined (b) Assets Current assets Cash and cash equivalents $ 802,328 $ 10,637,752 $ 11,440,080 Restricted cash
Full Press Release Details
Aytu BioScience, Inc.
Proforma Balance Sheet
June 30, 2017
Unaudited
6/30/2017
Pro Forma
Pro Forma
Consolidated
Adjustments (a)
Combined (b)
Assets
Current assets
Cash and cash equivalents
$
802,328
$
10,637,752
$
11,440,080
Restricted cash
75,214
75,214
Accounts receivable, net
528,039
-
528,039
Inventory, net
1,312,221
-
1,312,221
Prepaid expenses and other
310,760
-
310,760
Total current assets
3,028,562
10,637,752
13,666,314
Fixed assets, net
647,254
-
647,254
Developed technology, net
1,337,333
-
1,337,333
Customer contracts, net
77,667
-
77,667
Trade names, net
164,037
-
164,037
Natesto asset
9,231,072
-
9,231,072
Goodwill
238,426
-
238,426
Patents, net
271,278
-
271,278
Deposits
2,888
-
2,888
Total long-term assets
11,969,955
-
11,969,955
Total assets
$
14,998,517
$
10,637,752
$
25,636,269
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and other
$
2,220,400
$
-
$
2,220,400
Accrued liabilities
782,536
-
782,536
Accrued compensation
339,704
-
339,704
Deferred rent
6,673
-
6,673
Contingent consideration
261,155
-
261,155
Warrant derivative liability
-
3,323,411
3,323,411
Total current liabilities
3,610,468
3,323,411
6,933,879
Contingent consideration
7,386,782
-
7,386,782
Deferred rent
1,451
-
1,451
Total liabilities
10,998,701
3,323,411
14,322,112
Commitments and contingencies
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued
-
1
1
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued
and outstanding 824,831 in 2017 and 187,098 in 2016